Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
34 studies found for:    newlink
Show Display Options
Rank Status Study
1 Active, not recruiting Alternative Dosing for CRLX101 Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: CRLX101;   Drug: Bevacizumab;   Drug: mFOLFOX6
2 Completed CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: CRLX101;   Drug: Bevacizumab;   Drug: Standard of Care (Investigator Choice)
3 Completed
Has Results
A Phase 2 Study of CRLX101 in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: CRLX101;   Other: Best Supportive Care
4 Completed Vaccine Treatment for Hormone Refractory Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: HyperAcute-Prostate Cancer Vaccine
5 Terminated Vaccine Treatment for Advanced Breast Cancer
Condition: Breast Cancer
Intervention: Biological: HyperAcute - Breast cancer vaccine
6 Completed Vaccine Treatment for Advanced Malignant Melanoma
Condition: Malignant Melanoma
Intervention: Biological: HyperAcute-Melanoma Vaccine
7 Recruiting Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Conditions: Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor;   Ependymoma;   Medulloblastoma
Interventions: Drug: Indoximod;   Drug: Temozolomide;   Radiation: Conformal Radiation
8 Recruiting Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Progression of Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Recurrent
Interventions: Drug: Docetaxel;   Biological: Tergenpumatucel-L;   Drug: Indoximod 600mg;   Drug: Indoximod 1200mg
9 Terminated Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable
Interventions: Drug: mFOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: SBRT;   Drug: Gemcitabine
10 Recruiting Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Adenocarcinoma;   Metastatic Pancreatic Cancer
Interventions: Drug: Nab-Paclitaxel;   Drug: Gemcitabine;   Drug: Indoximod
11 Recruiting Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: Indoximod;   Drug: Ipilimumab;   Drug: Nivolumab;   Drug: Pembrolizumab
12 Recruiting Immunotherapy Study for Patients With Stage IV Melanoma
Conditions: Stage IV Melanoma;   Metastatic Melanoma
Interventions: Drug: HyperAcute®-Melanoma (HAM) Immunotherapy;   Drug: Ipilimumab;   Drug: Pembrolizumab;   Drug: Nivolumab
13 Recruiting Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Conditions: Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor
Interventions: Drug: Indoximod;   Drug: Temozolomide;   Drug: Bevacizumab;   Radiation: Stereotactic Radiation
14 Active, not recruiting Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions: Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
15 Active, not recruiting Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Docetaxel;   Other: Placebo;   Drug: Indoximod;   Drug: Paclitaxel
16 Active, not recruiting Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Progression of Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Recurrent
Interventions: Drug: Docetaxel;   Biological: HyperAcute®-Lung Immunotherapy;   Drug: Gemcitabine;   Drug: Pemetrexed
17 Completed Immunotherapy Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy;   Drug: Gemcitabine;   Radiation: 5FU Chemoradiation
18 Terminated IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
Conditions: Breast Cancer;   Lung Cancer;   Melanoma;   Pancreatic Cancer;   Solid Tumors
Intervention: Drug: 1-methyl-D-tryptophan
19 Terminated Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
20 Completed Vaccine Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine

   Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.